Incannex Healthcare Inc IXHL Stock Analysis
- Nasdaq
- Stock
- Market open · no trades yet today
$2.27 down $0.22, 8.84% at close Nov 5
Last close · Previous close $2.49
- Market cap
- $27.16MAt the Nov 5 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$2.27down $0.22, 8.84%Thu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.49Nov 4
- Volume123.33KNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume73.19KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.17 to $14.91; now $2.27
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
IXHL trailed the S&P 500 in all 4 periods.
| Period | IXHL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IXHL: down 29.3% S&P 500: down 5.4% | IXHL trailed the S&P 500 by 23.9 percentage points Trailed |
| 3M | IXHL: down 26.3% S&P 500: down 4.5% | IXHL trailed the S&P 500 by 21.8 percentage points Trailed |
| YTD | IXHL: down 78.9% S&P 500: up 8.3% | IXHL trailed the S&P 500 by 87.2 percentage points Trailed |
| 1Y | IXHL: down 79.9% S&P 500: up 9.3% | IXHL trailed the S&P 500 by 89.2 percentage points Trailed |
$10,000 invested in IXHL a year ago (Nov 5, 2025) would be worth about $2,008 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $10,934.
IXHL trailed the S&P 500 in all 4 periods.
| Period | IXHL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IXHL: down 29.3% S&P 500: down 5.4% | IXHL trailed the S&P 500 by 23.9 percentage points Trailed |
| 3M | IXHL: down 26.3% S&P 500: down 4.8% | IXHL trailed the S&P 500 by 21.5 percentage points Trailed |
| YTD | IXHL: down 78.9% S&P 500: up 7.5% | IXHL trailed the S&P 500 by 86.4 percentage points Trailed |
| 1Y | IXHL: down 79.9% S&P 500: up 8.2% | IXHL trailed the S&P 500 by 88.1 percentage points Trailed |
$10,000 invested in IXHL a year ago (Nov 5, 2025) would be worth about $2,008 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,818.
All-time high
$261.90
Closing high on . Now 99.1% below that record.
Split-adjusted daily closes since Nov 30, 2023.
Stock splits
2
Latest: 1-for-30 on . Share counts adjust after each split.
Both splits
- 1-for-30
- 1-for-4
Valuation
The Nov 5 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −47.41%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - −$40.46MAt the Nov 5 close
What it would cost to buy the whole business: the market cap at the Nov 5 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own IXHL DCF in Excel. Value Incannex Healthcare with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q4 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00down 100.0%
- Net income
- −$19.30M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q1 FY25 (Sep 30, 2024) | $74.00K | −$5.42M | Paused See the note under the price. |
| Q2 FY25 (Dec 31, 2024) | $12.00K | −$5.89M | Paused See the note under the price. |
| Q3 FY25 (Mar 31, 2025) | $0.00 | −$3.97M | Paused See the note under the price. |
| Q4 FY25 (Jun 30, 2025) | $0.00 | −$31.60M | Paused See the note under the price. |
| Q1 FY26 (Sep 30, 2025) | $0.00 | −$6.41M | Paused See the note under the price. |
| Q2 FY26 (Dec 31, 2025) | $0.00 | −$6.52M | Paused See the note under the price. |
| Q3 FY26 (Mar 31, 2026) | $0.00 | −$3.88M | Paused See the note under the price. |
| Q4 FY26 (Jun 30, 2026) | $0.00 | −$2.49M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (Jun 30, 2022) | $0.00 | −$14.90M | Paused See the note under the price. |
| FY23 (Jun 30, 2023) | $0.00 | −$48.81M | Paused See the note under the price. |
| FY24 (Jun 30, 2024) | $12.00K | −$18.46M | Paused See the note under the price. |
| FY25 (Jun 30, 2025) | $86.00K | −$46.89M | Paused See the note under the price. |
| FY26 (Jun 30, 2026) | $0.00 | −$19.30M | Paused See the note under the price. |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$12.88MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$12.87MLast 12 months
- Capital spending$10.00KLast 12 months
Shareholder returns
- $69.27MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $67.76MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$96.00KAs of Jun 30, 2026
- Net cash$67.67MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 48.81As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −26.3%Last 12 months
Over the last 12 months, Incannex Healthcare lost money: its net loss was 26.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −25.2%Last 12 months
Over the last 12 months, Incannex Healthcare’s net loss was 25.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Incannex Healthcare Inc
Incannex is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The company is advancing novel oral fix-dosed treatments and therapeutic regimens based on evidence-based innovation. Incannex's lead Phase 2/3 and Phase 2 clinical programs include IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide, designed to act synergistically in the treatment of OSA for the treatment of obstructive sleep apnea; IHL-675A, an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate, acting synergistically to alleviate inflammation, and PSX-001, an oral synthetic psilocybin treatment in combination with psychotherapy, for the treatment of generalized anxiety disorder. Incannex's programs target disorders that have limited, inadequate, or no approved pharmaceutical treatment options.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Australia
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
IXHL news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
IXHL stock FAQ
What is IXHL stock’s price today?
Incannex Healthcare (IXHL) traded at $2.27 at the close on , down $0.22 (8.84%) from the previous close of $2.49. Over the past 52 weeks it has traded between $2.17 and $14.91.
What is Incannex Healthcare’s market cap?
Incannex Healthcare’s market capitalization is about $27.2 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $2.27 (how market cap works).
Does IXHL pay a dividend?
Incannex Healthcare hasn’t paid a dividend in the last twelve months.
What is IXHL’s 52-week high and low?
Over the past 52 weeks IXHL has traded as low as $2.17 and as high as $14.91. At $2.27 at the close on , it is 84.8% below that high and 4.6% above the low.
What is IXHL’s all-time high?
IXHL’s highest closing price was $261.90 on , adjusted for stock splits. At $2.27 at the close on , it is 99.1% below that record.
Has IXHL stock ever split?
Yes, twice: 1-for-4 on ; 1-for-30 on .
How has IXHL stock performed?
Including dividends and measured to the close on , IXHL has returned −78.9% so far this year and −79.9% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.3% and +9.3%. Past performance doesn’t predict future returns.
What sector and industry is Incannex Healthcare in?
Incannex Healthcare is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is headquartered in Australia.
What exchange does IXHL trade on?
Incannex Healthcare trades on the Nasdaq under the ticker symbol IXHL. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.